AN2 Therapeutics Target Price

Where could ANTX trade next? Consensus target price: $9.

Get informed when a big investor buys or sells

+ Follow

Share Price

$5.71

Average Target Price

$9.00

57.6% upside

1 analysts in the last 4 months

High: $9 | Low: $9

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-07-20	Guggenheim	$9	57.6% upside
2026-05-14	Leerink PartnersJoseph Schwartz	$9	57.6% upside
2025-05-05	JMP SecuritiesRoy Buchanan	$2	65% downside
2024-07-03	Leerink PartnersJoseph Schwartz	$5	12.4% downside
2024-05-16	Evercore ISILiisa Bayko	$2	65% downside
2024-04-02	JMP SecuritiesRoy Buchanan	$6	5.1% upside
2022-11-14	Leerink Partners	$25	337.8% upside
2022-04-19	Evercore ISI	$25	337.8% upside
2022-04-19	Oppenheimer	$22	285.3% upside

AN2 Therapeutics (ANTX) FAQ

As of the most recent data, ANTX shows a target price of $9. Scroll down for historical charts and peer comparison views.

If AN2 Therapeutics moved to the average analyst target of $9, shares would be roughly 57.6% higher than $5.71. Treat that as a sentiment and modeling checkpoint rather than a precise forecast, and weigh it against your own view of AN2 Therapeutics's earnings trajectory.

Besides this target price page, Stockcircle has AN2 Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect target price (currently $9) with ownership activity and broader fundamentals.